Leadership

Clinical Leadership Team

Marc Fishman, MD

Executive Chairman

Dr. Fishman founded Oncology Analytics in 2009. Oncology Analytics has grown rapidly, currently providing comprehensive oncology benefits management for members of health plans diagnosed with cancer. Through clinical research, patented technology and patient-focused customer services, Oncology Analytics ensures treating oncologists have the information they need to deliver the most efficacious, least toxic and most affordable chemotherapy treatments available to their patients.

Inc. Magazine’s 2013 Inc. 500|5000 list named Oncology Analytics in the top 20 of the fastest growing private health care companies in the United States. Dr. Fishman is board-certified in Internal Medicine and Hematology. Dr. Fishman developed his perspective on health care management and funding mechanisms through a wide variety of clinical experiences, including work in Kenya, New Zealand, Canada and Australia, in addition to the United States. Seeing the differences in care delivery systems, policy priorities and financing methods has provided him with unique insights into opportunities for improvement in the United States, which he is bringing to the market through OA. His combination of more than 20 years of clinical treatment experience and exposure to multi-national health systems have reinforced his commitment to value-based care for providing quality cancer treatment to all those who need it in the face of the enormous costs, waste and poorly aligned incentives in medical care.

Richard Wilder, MD, MBA

Chief Medical Officer

Dr. Wilder obtained an MD degree from the University of Maryland and an MBA degree from Johns Hopkins University. He completed an internal medicine internship at the Greater Baltimore Medical Center, a radiation oncology residency at the University of Arizona, and an ASTRO research fellowship at the Stanford University Medical Center. Dr. Wilder is board-certified in radiation oncology. He has worked on the faculty of leading academic centers such as the University of California, San Francisco and the MD Anderson Cancer Center.

Recently, Dr. Wilder served for 2 1/2 years as interim chair of the Department of Radiation Oncology at the Moffitt Cancer Center. During this time, he worked on radiation oncology treatment guidelines. Also, he served for five years as a Kidney and Testicular Cancer Panel Member for the NCCN, helping to write national evidence-based treatment guidelines. In addition, since 2002 he has served nationally as an oral board examiner for the American Board of Radiology. Dr. Wilder joined Oncology Analytics in 2016 as its Chief Medical Officer.

Laura R. Bobolts, PharmD, BCOP

Senior Vice President, Pharmacy

Dr. Bobolts is a board-certified Oncology Pharmacist that serves as an oncology medical information resource for Oncology Analytics, responsible for providing recommendations for alternative therapy or support for existing anti-cancer treatment plans based on evidence-based medicine. She manages a team of oncology pharmacists, provides recommendations for oncology-related national drug policies, and performs population-based research.

She is a graduate of Nova Southeastern University’s College of Pharmacy and completed a Pharmacy Practice Residency at the James A. Haley Veterans’ Hospital. She began her career at Moffitt Cancer Center, first specializing in malignant hematology and later specializing in breast and gynecologic oncology where she established the role of a clinical oncology pharmacist in the Women’s Oncology Clinic at Moffitt Cancer Center — consulting with attending oncologists and devising treatment plans directly from the outpatient clinic.

She is a Clinical Affiliate Assistant Professor for Nova Southeastern University’s College of Pharmacy, lecturing on various topics such as oncology pharmacy therapeutics and pediatric leukemias, upon request. She developed an APPE (Advanced Pharmacy Practice Experience) at Oncology Analytics, to teach pharmacy students more about the practice of oncology pharmacy benefits management. She is published in Lancet Oncology, a peer reviewer for JAMA Oncology and Clinical Genitourinary Cancer, as well as an oncology pharmacy topic writer for www.idstewardship.com. Her main area of research interest is invasive breast cancer.

Graeme B. Bolger, MD

Medical Director

Dr. Bolger is a Medical Director of Oncology Analytics. He is board-certified in medical oncology and internal medicine. Dr. Bolger is a MD graduate of McGill University, Montreal, Canada. He completed his residency in Internal Medicine at The Johns Hopkins Hospital in Baltimore, MD, and a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center, New York, NY, and Fred Hutchinson Cancer Research Center, Seattle, WA.

Prior to joining Oncology Analytics, Dr. Bolger had 21 years of experience in academic medicine, as an Assistant Professor at the University of Utah Health Sciences Center and an Associate Professor at the University of Alabama, Birmingham, AL. He has published over 65 full-length research papers in peer-reviewed journals. He was a member of the NCCN guidelines panels in testis and kidney cancer for over six years.

Vincenzo De Masi, MD

Medical Director

Vincenzo De Masi is a board-certified Radiation Oncologist. He received his medical degree from the Universita degli Studi di Firenze, Faculty of Medicine and Surgery in Florence, Italy. He completed his residency in radiation oncology at University of Chicago, Department of Radiation and Cellular Oncology. In 1987, after completing his training, he relocated to Salisbury on the Eastern Shore of Maryland where he served as Assistant Chief in the Division of Radiation Oncology at Peninsula Regional Medical Center. In 1994, to demonstrate his commitment to cancer care in the community, he founded the Atlantic Cancer Center in Berlin, Maryland, to provide the surrounding community with high quality and comprehensive cancer treatment.

Dr. De Masi always had a strong academic interest and in 2004 he returned at University of Chicago as Associate Clinical Professor and Medical Director and Chief of Services in the Department of Radiation Oncology at University of Illinois, Chicago where he was involved in residents and medical students teaching, extensive clinical activities and numerous radiation therapy research projects. Dr. De Masi, has extensive experience in all aspects of radiation therapy including IMRT, IGRT and stereotactic radiosurgery, he has been personally involved in radiation treatment of more than 15,000 patients. He is the author of several publications and he has a special interest and expertise in breast, prostate, lung, lymphomas, CNS and gynecological malignancies. He was the recipient of the 2009 Terra del Sole Award from the Universita’ Del Salento Italy, for his achievements in medicine. He is a member of the AMA, ASTRO, ASCO, and the American Brachytherapy Society.

William C. Early, MD, PA

Medical Director

Dr. Early is a Medical Director at Oncology Analytics. He practiced hematology/oncology in South Florida for 29 years in solo practice and in partnership. Dr. Early received his medical degree from Indiana University School of Medicine. His residency was at the University of South Florida and fellowship at the University of South Carolina. He is board-certified in internal medicine and medical oncology. Dr. Early is bilingual and speaks Spanish.

Jurgen Kogler, MD

Medical Director

Dr. Kogler is a Medical Director at Oncology Analytics. He completed over five years of postgraduate training in medical oncology, including three years as a clinical and research fellow at Memorial Sloan Kettering Cancer Center. He is board-certified in internal medicine and medical oncology. He has practiced for 24 years in both the community and academic setting.

While in clinical practice, he was also an Associate Clinical Professor at UCLA and a teaching attending at Scripps Mercy in San Diego. Following his practicing years, he spent four years in clinical research at Quintiles and ICON.

Anna Schorer, MD

Medical Director, CMIO

Dr. Schorer focuses on clinical informatics and data management capabilities supporting our commitment to the delivery of safe, high-quality and cost-effective care for cancer patients. Prior to joining Oncology Analytics, Dr. Schorer was a clinician, educator and researcher in hematology and medical oncology at the Minneapolis VA Health Care System for more than two decades. In this position, she was a nationally known innovator in the design and optimization of electronic health systems and clinical decision support.

She conducted key health care improvement initiatives funded through the National Center for Patient Safety, the VA Office of Specialty Care Transformation, and the Midwest Health Care Network. Her project teams won awards for improving patient safety and care processes at the local, regional and national level. She also held a number of leadership roles within the Veterans Health Administration.

Dr. Schorer received her MD degree and did her Internal Medicine Residency at the University of Minnesota. She completed a Hematology/Medical Oncology Fellowship at the University of Washington and the University of Minnesota. She is board-certified in hematology, medical oncology, and clinical informatics, in addition to holding a Certificate in Clinical Informatics from the American Medical Informatics Association.

William Shimp, MD

Medical Director

Dr. Shimp is board-certified in internal medicine and medical Oncology. He has been in medical oncology practice for the past 30 years, at both Park Nicollet Medical Center in Minneapolis and at Affiliated Community Medical Centers in Willmar, Minnesota.

Dr. Shimp served as Chief of Staff at Park Nicollet Methodist Hospital in Minneapolis and was also Executive Vice-President and Chief Medical Officer for Park Nicollet Health Services, a group practice of over 700 physicians. He has enjoyed the opportunity to serve on numerous governing boards of medical institutions in the Twin Cities and outstate areas of Minnesota. He has authored numerous articles in the field of medical oncology.

Rakhi Gavan, PharmD, BCOP

Director of Oncology Pharmaceutical Affairs

As director of the pharmacy team, Dr. Gavan utilizes evidence-based medicine and evaluates individual medical histories to ensure that patients receive the most appropriate, cost-effective treatment options available. She has nearly a decade of clinical experience in oncology with a special interest in hematology and hematopoietic stem cell transplantation. She comes to Oncology Analytics after previous tenures at Memorial Cancer Institute-West, Jackson Memorial Hospital in Miami, and the University of Texas Medical Branch. Dr. Gavan is a board-certified Oncology Pharmacist earning her Doctor of Pharmacy degree from the University of Houston College of Pharmacy and completing postgraduate ASHP-accredited residencies in Pharmacy Practice at Baylor University Medical Center and Oncology Pharmacy at Audie L. Murphy Veterans Memorial Hospital/The University of Texas Health Sciences Center at San Antonio.

Marjorie Velasquez, PharmD

Clinical Oncology Pharmacist

Marjorie is a clinical oncology pharmacist with more than a decade of clinical and managed care experience. She helps clients evaluate their clinical drug policies by reviewing prior authorization requests to determine eligibility and recommends changes that will improve patient outcomes and optimize healthcare resources. Previously, Marjorie was a clinical pharmacist with PrescribIt RX and led the initiation of Humana’s Pilot Hospital Post-Discharge Program resulting in fewer readmissions and improved patient outcomes. In the Specialty Department at Humana, she dispensed and reviewed prior authorization requests for multiple medications including oncology and verified prescriptions for chemotherapy agents. She has also been a Retail Pharmacist with Walgreens. She earned a Doctor of Pharmacy degree from Nova Southeastern University in Florida.

Rebecca Tombleson, PharmD, BCOP

Clinical Oncology Pharmacist

As a clinical oncology pharmacist, Rebecca conducts high level reviews of patient information to determine the appropriateness of requested therapeutic agents. She is also responsible for alerting the OA team to any new medications, indications, and research associated with cancer treatment. She earned her Doctor of Pharmacy degree in 2008 from the University of South Carolina College of Pharmacy and then completed a residency at the University of Arizona Medical Center. In her prior position at Moffitt Cancer Center, she completed an Oncology Specialty Residency before transitioning into a clinical pharmacist role. She is currently a member of the University of South Florida’s Scientific Institutional Review Board.